CAR-T cell therapy

CAR-T cell therapy is a personalised immunotherapy that engineers a patient's T cells to target cancer, mainly certain blood cancers, and as of 2023 there were 6 commercially available CAR-T products discussed in a major review of long-term outcomes. It is used most often for some leukaemias, lymphomas, and multiple myeloma, usually when the disease has returned or not responded to standard treatment. The most important practical fact for patients is that CAR-T is highly specialised and can cause serious early toxicities, especially cytokine release syndrome and neurologic side effects, so it is given only in experienced centres with close monitoring.

What it is

CAR-T stands for chimeric antigen receptor T-cell therapy. It is a form of adoptive cellular immunotherapy in which a patient's own T cells, a type of white blood cell, are collected from the blood, genetically modified in a laboratory, expanded, and then infused back into the patient.

The engineered receptor helps the T cells recognise a chosen target, called an antigen, on cancer cells. In current routine practice, the best-established targets are CD19 for several B-cell leukaemias and lymphomas, and BCMA for multiple myeloma.

A simplified treatment pathway is:

1. Leukapheresis: T cells are collected from blood.
2. Manufacturing: The cells are genetically modified and multiplied.
3. Bridging therapy: Some patients need treatment while waiting for the product.
4. Lymphodepleting chemotherapy: Usually given shortly before infusion.
5. CAR-T infusion: The engineered cells are returned to the bloodstream.
6. Monitoring: Patients are watched closely for complications and response.

CAR-T is different from standard chemotherapy. Chemotherapy directly damages fast-growing cells. CAR-T aims to redirect the immune system to find and kill cancer cells.

How it works

The synthetic CAR combines an antigen-recognition part with internal signaling parts that activate the T cell. Unlike normal T-cell recognition, CARs can bind directly to a surface antigen on the cancer cell without needing the usual antigen presentation machinery.

Once infused, CAR-T cells can:

• bind to the target antigen on cancer cells
• become activated and multiply
• release immune signals and kill target cells
• sometimes persist for months or longer

This persistence is one reason some remissions can be durable. However, it also contributes to some side effects. For example, strong immune activation can trigger cytokine release syndrome (CRS), a systemic inflammatory reaction that may cause fever, low blood pressure, low oxygen levels, and organ dysfunction. Neurologic toxicity, now often grouped under immune effector cell-associated neurotoxicity syndrome, can cause confusion, tremor, speech problems, seizures, or reduced alertness.

Evidence and uses

CAR-T has shown the clearest benefit in relapsed or refractory blood cancers. These include certain:

Cancer type	Common target	Examples of use
B-cell acute lymphoblastic leukaemia	CD19	Children and adults in selected settings
Large B-cell lymphomas	CD19	After relapse or failure of prior therapy
Mantle cell lymphoma	CD19	Relapsed or refractory disease
Follicular lymphoma	CD19	Selected relapsed cases
Multiple myeloma	BCMA	Relapsed or refractory disease

Major reviews report that some patients achieve deep remissions, including remissions lasting years. Long-term follow-up has been one of the most important developments in the field because it shows that a subset of patients can remain disease-free well beyond the initial treatment period.

That said, CAR-T is not a guaranteed cure. Some cancers relapse after an initial response. Reasons include loss of the target antigen, poor persistence of CAR-T cells, and T-cell dysfunction or exhaustion. CAR-T has also been much harder to translate to solid tumours because of issues such as tumour heterogeneity, an immunosuppressive tumour microenvironment, and difficulty getting T cells to work effectively inside solid masses.

In India, CAR-T access is growing but remains limited to specialised centres because manufacturing, supportive care, and toxicity management are complex. Cost, logistics, and the need for trained multidisciplinary teams are major practical barriers. For patients in India, referral timing matters because people with rapidly progressing disease may become too unwell while waiting for manufacturing.

Safety and interactions

CAR-T is not a medicine people take at home, but it still has major safety issues that patients and families should understand.

Important risks include:

• Cytokine release syndrome (CRS): often begins in the first days after infusion; fever is common and severe cases can be life-threatening.
• Neurologic toxicity: confusion, difficulty speaking, drowsiness, tremor, or seizures can occur.
• Infections: risk is increased by prior cancer treatment, lymphodepleting chemotherapy, low blood counts, and immune suppression.
• Prolonged low blood counts: anaemia, neutropenia, and thrombocytopenia may last weeks or longer.
• B-cell aplasia and low immunoglobulins: especially with CD19-targeted therapy, which can increase infection risk.
• Tumour lysis syndrome: rapid cancer-cell breakdown in some patients.
• Rare second cancers: regulators and researchers are monitoring uncommon reports of secondary T-cell cancers after CAR-T.

Patients are usually advised to stay near the treating centre for a period after infusion and to avoid driving for some time because delayed neurologic effects can occur. Vaccination, infection prevention, blood product support, and immunoglobulin replacement may be part of follow-up care.

Because treatment plans vary, patients should discuss all current medicines with the oncology team, including steroids, anticoagulants, anti-infectives, and supplements. Some medicines may affect timing, infection risk, or supportive care. Do not start herbal products or over-the-counter immune boosters without asking the treating team.

When to see a clinician

Anyone who has recently received CAR-T should seek urgent medical care for:

• fever or chills
• shortness of breath
• dizziness or fainting
• confusion or unusual sleepiness
• trouble speaking or writing
• seizures
• severe headache
• bleeding or signs of infection

Even symptoms that seem mild can worsen quickly after CAR-T. Patients should carry their treatment information and contact details for the CAR-T centre, because emergency teams may need to coordinate with the specialist unit.

Limitations and open questions

CAR-T is one of the most important advances in blood-cancer treatment, but it has limits. It is not suitable for every patient, does not work for every cancer, and can cause severe toxicity. Access is uneven, especially in low- and middle-income settings.

Evidence is strongest for specific blood cancers and weaker for solid tumours. Researchers are studying ways to improve durability, reduce relapse, shorten manufacturing time, and make products safer. Areas of active research include dual-target CARs, allogeneic or "off-the-shelf" CAR-T products, better toxicity prediction, and strategies to overcome T-cell exhaustion.

There is also ongoing surveillance for rare long-term harms, including secondary malignancies. Current evidence suggests these events are uncommon, but follow-up is still important. For patients and families, the key question is not whether CAR-T is a breakthrough in general, but whether it fits the exact cancer type, prior treatments, disease pace, overall health, and the expertise available at the treating centre.